YELARIAT Trademark

Trademark Overview


On Thursday, May 3, 2018, a trademark application was filed for YELARIAT with the United States Patent and Trademark Office. The USPTO has given the YELARIAT trademark a serial number of 87905934. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, December 27, 2021. This trademark is owned by Eli Lilly and Company. The YELARIAT trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment of alopecia, Alzheimer's disease, atopic dermatitis, autoimmune diseases and disorders, bone and skeletal diseases and disorders, cancer, cardiovascular diseases, central nervous system diseases and disorders, cluster headaches, Crohn's disease, dementia, dermatological diseases and disorders, diabetes, dyslipidemia, endocrine diseases and disorders, gastrointestinal diseases and disorders, headaches, heart failure, inflammation and inflammatory diseases and disorders, inflammatory bowel disease, kidney diseases and disorders, liver diseases and disorders, lupus, mental disorders, metabolic diseases and disorders, migraines, neurodegenerative diseases and disorders, neurological disorders, obesity, pain, Parkinson's disease, Psoriasis, Psoriatic arthritis, rheumatoid arthritis, ulcerative colitis; Diagnostic agents and substances for medical purposes; radiopharmaceutical diagnostic preparations for use i...
yelariat

General Information


Serial Number87905934
Word MarkYELARIAT
Filing DateThursday, May 3, 2018
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateMonday, December 27, 2021
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, September 25, 2018

Trademark Statements


Goods and ServicesPharmaceutical preparations, namely, pharmaceutical preparations for the treatment of alopecia, Alzheimer's disease, atopic dermatitis, autoimmune diseases and disorders, bone and skeletal diseases and disorders, cancer, cardiovascular diseases, central nervous system diseases and disorders, cluster headaches, Crohn's disease, dementia, dermatological diseases and disorders, diabetes, dyslipidemia, endocrine diseases and disorders, gastrointestinal diseases and disorders, headaches, heart failure, inflammation and inflammatory diseases and disorders, inflammatory bowel disease, kidney diseases and disorders, liver diseases and disorders, lupus, mental disorders, metabolic diseases and disorders, migraines, neurodegenerative diseases and disorders, neurological disorders, obesity, pain, Parkinson's disease, Psoriasis, Psoriatic arthritis, rheumatoid arthritis, ulcerative colitis; Diagnostic agents and substances for medical purposes; radiopharmaceutical diagnostic preparations for use in the diagnosis of neurodegenerative diseases and of oncology and of pain

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateSaturday, May 12, 2018
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameEli Lilly and Company
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressIndianapolis, IN 46285

Party NameEli Lilly and Company
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressIndianapolis, IN 46285

Trademark Events


Event DateEvent Description
Monday, December 27, 2021ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Monday, December 27, 2021ABANDONMENT - NO USE STATEMENT FILED
Tuesday, April 20, 2021NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, April 19, 2021EXTENSION 5 GRANTED
Thursday, April 15, 2021EXTENSION 5 FILED
Thursday, April 15, 2021TEAS EXTENSION RECEIVED
Thursday, November 5, 2020NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, November 4, 2020EXTENSION 4 GRANTED
Monday, October 26, 2020EXTENSION 4 FILED
Wednesday, November 4, 2020CASE ASSIGNED TO INTENT TO USE PARALEGAL
Monday, October 26, 2020TEAS EXTENSION RECEIVED
Saturday, April 18, 2020NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, April 16, 2020EXTENSION 3 GRANTED
Thursday, April 16, 2020EXTENSION 3 FILED
Thursday, April 16, 2020TEAS EXTENSION RECEIVED
Thursday, October 17, 2019NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, October 15, 2019EXTENSION 2 GRANTED
Tuesday, October 15, 2019EXTENSION 2 FILED
Tuesday, October 15, 2019TEAS EXTENSION RECEIVED
Thursday, April 11, 2019NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, April 9, 2019EXTENSION 1 GRANTED
Tuesday, April 9, 2019EXTENSION 1 FILED
Tuesday, April 9, 2019TEAS EXTENSION RECEIVED
Tuesday, November 20, 2018NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, September 25, 2018OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, September 25, 2018PUBLISHED FOR OPPOSITION
Wednesday, September 5, 2018NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Thursday, August 23, 2018APPROVED FOR PUB - PRINCIPAL REGISTER
Saturday, August 18, 2018ASSIGNED TO EXAMINER
Saturday, May 12, 2018NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
Monday, May 7, 2018NEW APPLICATION ENTERED IN TRAM